Clinical trials: Insomnia Chronic
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Insomnia
A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia
This is a randomized, double-blind, placebo-controlled, multicenter trial with a 4-way crossover design. Elderly subjects with primary insomnia who meet screening requirements will initially be randomized into the study and…
- Trial name
- NCT00748592
- Testing
- PD 0200390
- Sponsor
- Pfizer
Insomnia Chronic, Insomnia Disorder
Digital CBT-I for Chronic Insomnia
This study evaluates the effectiveness and safety of a digital Cognitive Behavioral Therapy program for Insomnia (CBT-I) in individuals with chronic insomnia.
- Trial name
- NCT06695000
- Testing
- digital CBT-I
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- WELT corp
Sleep Initiation and Maintenance Disorders, Mental Disorders
A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
To investigate the long-term efficacy and safety of treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo, in participants with chronic primary insomnia.
- Conditions
- Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders
- Trial name
- NCT00631657
- Testing
- Esmirtazapine
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects with primary insomnia on subjective sleep measures, compared to placebo.
- Trial name
- NCT00352144
- Testing
- Eszopiclone
- Where
- 58 sites in United States
- Volunteers
- 830 people
- Sponsor
- Sumitomo Pharma America, Inc.
Insomnia
Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)
This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706) (NCT00482612) or 176002 (P05707) (NCT00506389).
- Trial name
- NCT00610675
- Testing
- Org 50081
- Volunteers
- 346 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Insomnia
Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia
This purpose of this study is to evaluate the safety and effectiveness of Ramelteon, once daily (QD), in elderly participants with chronic insomnia.
- Trial name
- NCT00671255
- Testing
- Ramelteon
- Where
- 115 sites in United States, Canada
- Volunteers
- 829 people
- Sponsor
- Takeda
Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder
A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and…
- Conditions
- Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias, Sleep Disorders
- Trial name
- Jade (NCT00561574)
- Testing
- Esmirtazapine
- Volunteers
- 259 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia
The purpose of this study is to determine the efficacy and safety of ramelteon, once daily (QD), taken in combination with Gabapentin for treating insomnia.
- Trial name
- NCT00755508
- Testing
- Ramelteon and gabapentin, Ramelteon, Gabapentin
- Volunteers
- 378 people
- Sponsor
- Takeda
Chronic Insomnia
Comparing Insomnia Care As Usual to Digital Augmentation (CICADA)
The purpose of this pragmatic non-inferiority randomized clinical trial is to evaluate whether Cognitive Behavioral Treatment of Insomnia (CBTI) delivered through a clinical decision support digital platform is non-inferior to…
- Trial name
- NCT05490550
- Testing
- COAST-enhanced CBTI, Military Treatment Facility Insomnia Care As Usual
- Where
- United States
- Volunteers
- 188 people
- Sponsor
- Noctem, LLC
Insomnia
Safety and Efficacy Study of APD125 in Patient With Insomnia
The purpose of this study is to determine the effects of APD125 in patients with sleep maintenance insomnia.
- Trial name
- NCT00452179
- Testing
- APD125
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Arena Pharmaceuticals
Sleep Initiation and Maintenance Disorders, Mental Disorders
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
This trial is a 26-week, open label extension trial to investigate safety and explore efficacy of esmertazapine in participants with insomnia who completed protocol 21106/P05701/MK-8265-002 (NCT00631657).
- Conditions
- Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders
- Trial name
- NCT00750919
- Testing
- esmirtazapine
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Insomnia
Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia
The purpose of this study is to assess whether ramelteon, once daily (QD), can facilitate the discontinuation of zolpidem in subjects with chronic insomnia.
- Trial name
- NCT00492232
- Testing
- Ramelteon and zolpidem
- Where
- 41 sites in United States
- Volunteers
- 135 people
- Sponsor
- Takeda
Chronic Insomnia Characterized
Comparative Pharmacokinetic Study of Ramelteon Modified-Release Tablets and Ramelteon Tablets in Healthy Subjects
A randomized, open-label, two-period, double-crossover comparative pharmacokinetic (PK) study of a single oral dose of Ramelteon Modified-Release Tablets and Ramelteon Tablets in Chinese healthy subjects Primary objective: To…
- Trial name
- NCT06890715
- Testing
- Test product (T): Ramelteon Modified-Release Tablets, Reference product (R): Ramelteon Tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Insomnia, Insomnia Chronic
Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator Device (CES) for the treatment of insomnia characterized by difficulties with sleep maintenance using a 20-minute treatment right before…
- Conditions
- Insomnia, Insomnia Chronic, Sleep
- Trial name
- NCT04627480
- Testing
- Fisher Wallace Neurostimulation Device
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ProofPilot
Insomnia, Insomnia Chronic
Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder
The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.
- Trial name
- TINA (NCT07420816)
- Testing
- APSTZD 1, APSTZD 2, APSTZD 3
- Where
- Brazil
- Volunteers
- 222 people
- Sponsor
- Apsen Farmaceutica S.A.
Balance
Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia
The purpose of the study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), compared to placebo with Zopiclone in adults with chronic insomnia
- Trial name
- NCT00237497
- Testing
- Ramelteon, Zopiclone
- Where
- United Kingdom
- Volunteers
- 275 people
- Sponsor
- Takeda
Primary Insomnia
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
- Trial name
- RESTORA 1 (NCT00608985)
- Testing
- almorexant, zolpidem
- Where
- 91 sites in Australia, Austria and 18 more
- Volunteers
- 709 people
- Sponsor
- Midnight Pharma, LLC
Chronic Insomnia
A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic
The purpose of the study is to collect data in a real-world environment, for a digital therapeutic that delivers CBT-I through a decentralized clinical trial, open to participants with chronic insomnia.
- Trial name
- DREAM (NCT04325464)
- Testing
- PEAR-003A
- Where
- United States
- Volunteers
- 1,590 people
- Sponsor
- Pear Therapeutics, Inc.
Primary Insomnia, Secondary Insomnia
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
- Trial name
- SLUMBER (NCT00784875)
- Testing
- LY2624803, zolpidem
- Where
- 49 sites in United States
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company